Livforsakringsbolaget Skandia’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $18.3M | Buy |
30,900
+9,700
| +46% | +$4.83M | 0.71% | 33 |
|
|
2025
Q4 | $10.3M | Buy |
21,200
+20,800
| +5,200% | +$9.69M | 0.4% | 61 |
|
|
2025
Q3 | $168K | Hold |
400
| – | – | 0.01% | 391 |
|
|
2025
Q2 | $115K | Sell |
400
-20,600
| -98% | -$6.16M | 0.01% | 473 |
|
|
2025
Q1 | $6.47M | Sell |
21,000
-7,100
| -25% | -$2.43M | 0.37% | 73 |
|
|
2024
Q4 | $9.9M | Buy |
28,100
+27,700
| +6,925% | +$10.2M | 0.52% | 43 |
|
|
2024
Q3 | $143K | Sell |
400
-20,450
| -98% | -$6.91M | 0.01% | 472 |
|
|
2024
Q2 | $6.64M | Buy |
20,850
+4,600
| +28% | +$1.22M | 0.54% | 47 |
|
|
2024
Q1 | $3.73M | Hold |
16,250
| – | – | 0.32% | 77 |
|
|
2023
Q4 | $3.57M | Hold |
16,250
| – | – | 0.34% | 74 |
|
|
2023
Q3 | $3.66M | Buy |
16,250
+1,400
| +9% | +$322K | 0.4% | 68 |
|
|
2023
Q2 | $3.28M | Buy |
14,850
+300
| +2% | +$66.5K | 0.34% | 81 |
|
|
2023
Q1 | $3.26M | Buy |
14,550
+10,850
| +293% | +$2.67M | 0.34% | 80 |
|
|
2022
Q4 | $1.03M | Hold |
3,700
| – | – | 0.12% | 163 |
|
|
2022
Q3 | $774K | Hold |
3,700
| – | – | 0.1% | 161 |
|
|
2022
Q2 | $872K | Hold |
3,700
| – | – | 0.08% | 183 |
|
|
2022
Q1 | $663K | Hold |
3,700
| – | – | 0.04% | 230 |
|
|
2021
Q4 | $798K | Buy |
3,700
+700
| +23% | +$137K | 0.05% | 228 |
|
|
2021
Q3 | $554K | Hold |
3,000
| – | – | 0.03% | 316 |
|
|
2021
Q2 | $538K | Hold |
3,000
| – | – | 0.03% | 337 |
|
|
2021
Q1 | $502K | Hold |
3,000
| – | – | 0.04% | 318 |
|
|
2020
Q4 | $455K | Hold |
3,000
| – | – | 0.04% | 328 |
|
|
2020
Q3 | $303K | Hold |
3,000
| – | – | 0.03% | 315 |
|
|
2020
Q2 | $363K | Hold |
3,000
| – | – | 0.04% | 275 |
|
|
2020
Q1 | $284K | Sell |
3,000
-1,239
| -29% | -$118K | 0.04% | 281 |
|
|
2019
Q4 | $373K | Hold |
4,239
| – | – | 0.04% | 262 |
|
|
2019
Q3 | $338K | Hold |
4,239
| – | – | 0.04% | 301 |
|
|
2019
Q2 | $331K | Sell |
4,239
-400
| -9% | -$37.4K | 0.04% | 297 |
|
|
2019
Q1 | $545K | Hold |
4,639
| – | – | 0.07% | 214 |
|
|
2018
Q4 | $506K | Hold |
4,639
| – | – | 0.08% | 207 |
|
|
2018
Q3 | $593K | Sell |
4,639
-1,000
| -18% | -$124K | 0.07% | 226 |
|
|
2018
Q2 | $639K | Hold |
5,639
| – | – | 0.06% | 284 |
|
|
2018
Q1 | $633K | Hold |
5,639
| – | – | 0.06% | 269 |
|
|
2017
Q4 | $834K | Sell |
5,639
-200
| -3% | -$25.4K | 0.08% | 225 |
|
|
2017
Q3 | $685K | Sell |
5,839
-2,922
| -33% | -$373K | 0.06% | 291 |
|
|
2017
Q2 | $1.14M | Hold |
8,761
| – | – | 0.1% | 202 |
|
|
2017
Q1 | $1.19M | Sell |
8,761
-900
| -9% | -$136K | 0.11% | 184 |
|
|
2016
Q4 | $1.39K | Sell |
9,661
-134,875
| -93% | -$17.2M | 0.07% | 293 |
|
|
2016
Q3 | $9.03M | Buy |
144,536
+127,835
| +765% | +$15.4M | 0.44% | 43 |
|
|
2016
Q2 | $1.77M | Hold |
16,701
| – | – | 0.08% | 291 |
|
|
2016
Q1 | $1.86M | Hold |
16,701
| – | – | 0.09% | 252 |
|
|
2015
Q4 | $2.62M | Buy |
16,701
+3,100
| +23% | +$451K | 0.12% | 178 |
|
|
2015
Q3 | $1.78M | Buy |
13,601
+2,000
| +17% | +$321K | 0.09% | 247 |
|
|
2015
Q2 | $2.02M | Sell |
11,601
-2,602
| -18% | -$468K | 0.1% | 243 |
|
|
2015
Q1 | $2.45M | Hold |
14,203
| – | – | 0.12% | 198 |
|
|
2014
Q4 | $1.84M | Hold |
14,203
| – | – | 0.09% | 278 |
|
|
2014
Q3 | $1.83M | Hold |
14,203
| – | – | 0.07% | 336 |
|
|
2014
Q2 | $1.26M | Hold |
14,203
| – | – | 0.05% | 455 |
|
|
2014
Q1 | $1.34M | Hold |
14,203
| – | – | 0.05% | 421 |
|
|
2013
Q4 | $1.61M | Buy |
14,203
+3,800
| +37% | +$343K | 1.04% | 24 |
|
|
2013
Q3 | $820K | Buy |
+10,403
| New | +$760K | 0.57% | 68 |
|
Other funds holding UTHR
ACA
VPM
VCM
Livforsakringsbolaget Skandia's UTHR Position: Q1 2026 in Review
Livforsakringsbolaget Skandia increased its United Therapeutics (UTHR) stake by 46% in Q1 2026, buying an estimated $4.83M and bringing the position to 30,900 shares worth $18.3M. The position accounts for 0.71% of the portfolio, ranked #33.
Livforsakringsbolaget Skandia first reported a position in UTHR in Q3 2013 and has held it in 51 quarters since. 852 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.
- Livforsakringsbolaget Skandia held 30,900 shares of United Therapeutics worth $18.3M as of Q1 2026.
- Livforsakringsbolaget Skandia bought 9,700 United Therapeutics shares in Q1 2026, an estimated $4.83M.
- United Therapeutics made up 0.71% of Livforsakringsbolaget Skandia's portfolio in Q1 2026, its #33 holding.
- Livforsakringsbolaget Skandia first reported a position in United Therapeutics in Q3 2013 and has held it in 51 quarters since.
- 852 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.
Based on Livforsakringsbolaget Skandia's 13F filing for Q1 2026, filed 5 May 2026.